Proactiveinvestors recommends
Additional Information
Market: NYSE AMEX
Sector: Pharmaceuticals
EPIC: NBS
NeoStem
www.neostem.com

NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.

Full NeoStem profile here
Pdf

NeoStem's Vatican conference sees Thompson urge Obama for US stem cell commission

9th Nov 2011, 4:05 pm by Olivia D'Orazio
NeoStem's Vatican conference sees Thompson urge Obama for US stem cell commission

At NeoStem's (AMEX:NBS) Vatican conference, co-hosted under NeoStem's partnership with the Vatican's Pontifical Council for Culture (PCC), former U.S. Health and Human Services Secretary, Tommy G. Thompson, urged President Obama to establish a commission that will fund research for adult stem cells on Wednesday.

The three-day conference is taking place at the Vatican in Rome, Italy, and is being co-hosted by U.S.-based NeoStem, a research firm devoted to the application of adult stem cells for the treatment of a variety of disorders.

At the conference, Thompson, who intends to run for U.S. Senate in the next election, said he hopes to see a body created within the National Institutes of Health that will "be able to use the resources that we have in America to really put regenerative medicine into the forefront of therapies creating new breakthroughs in disease control."

Thompson said the commission would involve private sector business leaders who would evaluate federal efforts surrounding regenerative medicine. The group would make recommendations to Obama's administration regarding the coordination of regenerative research, uniting them with private enterprises.

NeoStem CEO, Dr. Robin Smith said: "I think it is very important to get Congress and different political leaders like President Obama to understand adult stem cells, [so that] we can unite to get a more impactful outcome, decreasing needless human suffering by getting these therapies into clinics."

The conference is part of NeoStem's partnership with the Vatican's Pontifical Council for Culture (PCC), and is driven by NeoStem's charitable Stem for Life Foundation, and the PCC's Science Theology and the Ontological Quest International.

The partnership, originally forged in May 2010, is intended to advance the use of adult stem cells by fostering scientific research and exploring the cultural, ethical and human implications of their use.

The conference is being attended by Church leaders, policymakers, ethicists, representatives from the stem cell business community and ministers of health from around the world, among others. Attendees are taking part in a variety of events, including keynote speakers, discussion panels, patient case studies and breakout sessions.

"This conference is going to dispel a lot of the old myths and bring in a lot of education, a lot of new scientists and new reports are going to be discussed that is going to help the world discuss adult stem cells in a new and better light," Thompson added.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.